NCT06691152 (SLE) is a Phase 1 clinical trial of CD19 Universal CAR-T cells in Systemic Lupus Erythematosus, sponsored by The Children's Hospital of Zhejiang University School of Medicine.

Who is sponsoring NCT06691152?

NCT06691152 is sponsored by The Children's Hospital of Zhejiang University School of Medicine.

What drugs are being tested in NCT06691152?

Interventions in NCT06691152: CD19 Universal CAR-T cells.

What condition does NCT06691152 study?

NCT06691152 studies Systemic Lupus Erythematosus.

Is NCT06691152 still recruiting?

NCT06691152 is currently recruiting now. Last updated 15 November 2024.

Last reviewed 2024-11-15 · How we verify

NCT06691152: SLE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus

Recruiting now Phase 1 Last updated 15 November 2024

What this trial tests

Phase 1 trial testing CD19 Universal CAR-T cells in Systemic Lupus Erythematosus in 18 participants. Currently enrolling.

Timeline

30 October 2024

Primary endpoint
30 September 2027

30 September 2027

Quick facts

Lead sponsor	The Children's Hospital of Zhejiang University School of Medicine
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	30 October 2024
Primary completion	30 September 2027
Estimated completion	30 September 2027
Sites	1 location across China

Drugs / interventions tested

CD19 Universal CAR-T cells — full drug profile →

Conditions studied

Systemic Lupus Erythematosus — all drugs for Systemic Lupus Erythematosus →

Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Who can join

5 and older, any sex, with Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an investigator-initiated trial to evaluate the safety and efficacy of CD19 Universal CAR-T cells in the treatment of refractory systemic lupus erythematosus.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-based cell therapy for autoimmune diseases.
Li X, He C, Wang K, Xu GY, et al · · 2025 · cited 2× · PMID 41050649 · DOI 10.3389/fimmu.2025.1613622
Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions.
Alsayb MA. · · 2025 · cited 2× · PMID 41041324 · DOI 10.3389/fimmu.2025.1647066
Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases.
Jiang M, Zhao J, Yuan J, Yu Z, et al · · 2025 · cited 2× · PMID 40747591 · DOI 10.1080/21645515.2025.2538350
Roads and detours for CAR T cell therapy in autoimmune diseases.
Avouac J, Barzel A, Caiati D, Davis RS, et al · · 2026 · cited 1× · PMID 41588112 · DOI 10.1038/s41573-025-01349-4
Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.
Natoli V, Charras A, Smith EM, Hedrich CM. · · 2025 · cited 1× · PMID 41410901 · DOI 10.1007/s11926-025-01207-7
CAR T cells in pediatric systemic lupus erythematosus.
Simopoulou T, Gkoutzourelas A, Katsiari CG. · · 2026 · cited 1× · PMID 40646368 · DOI 10.1007/s10067-025-07550-5
Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease.
Osborne M, Maher J. · · 2025 · PMID 41463563 · DOI 10.3390/biology14121790
CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases.
Wu Y, Han L, Wang Y, Gu M, et al · · 2025 · PMID 40881712 · DOI 10.3389/fimmu.2025.1625166

Verify or expand the search:

Other recruiting trials for Systemic Lupus Erythematosus

Currently open trials in the same condition.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
NCT07371468 — A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) · Phase 1 · recruiting

Other The Children's Hospital of Zhejiang University School of Medicine trials

Trials by the same sponsor.

NCT07368504 — AI for Newborn Metabolic Screening · NA · not yet recruiting
NCT07499154 — Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery · Phase 4 · not yet recruiting
NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
NCT07496541 — Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis · not yet recruiting
NCT07045844 — Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06691152 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Children's Hospital of Zhejiang University School of Medicine
Last refreshed: 15 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06691152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing